Palbociclib in Patients With Soft Tissue Sarcoma With
Publication Title
JCO Precis Oncol
Document Type
Article
Publication Date
7-1-2024
Keywords
Humans; Cyclin-Dependent Kinase 4; Pyridines; Female; Male; Middle Aged; Piperazines; Adult; Aged; Sarcoma; Registries; Gene Amplification; Young Adult; Aged, 80 and over; washington; swedish; swedish cancer
Abstract
PURPOSE: Targeted Agent and Profiling Utilization Registry (TAPUR) is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations known to be drug targets. Results of a cohort of patients with soft tissue sarcoma with cyclin-dependent kinase 4 (
METHODS: Eligible patients had measurable disease, Eastern Cooperative Oncology Group performance status 0 to 2, adequate organ function, and no standard treatment options. The primary end point was disease control (DC), defined as objective response (OR) or stable disease (SD) of at least 16+ weeks duration (SD16+) according to RECIST v1.1. The DC rate was estimated with a 90% CI. Secondary end points included OR, progression-free survival (PFS), overall survival (OS), duration of response, duration of SD, and safety.
RESULTS: Forty-two patients with
CONCLUSION: Palbociclib met prespecified criteria to declare a signal of antitumor activity in patients with sarcoma and
Clinical Institute
Cancer
Specialty/Research Institute
Oncology
Specialty/Research Institute
Internal Medicine
DOI
10.1200/PO.24.00219
